Evidence map›Paper›PMID 37835418›Full record

ArticleCancers2023

World's First Long-Term Colorectal Cancer Model by 3D Bioprinting as a Mechanism for Screening Oncolytic Viruses.

Colin McGuckin, Nico Forraz, Clément Milet, Mathieu Lacroix, Yordan Sbirkov, Victoria Sarafian, Caroline Ebel, Anita Spindler, Véronique Koerper, Jean-Marc Balloul and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Colin McGuckinCTIPharma Department, Cell Therapy Research Institute, CTIBIOTECH, Bat A16, 5 Avenue Lionel Terray, Meyzieu, 69330 Lyon, France.ORCID 0000-0001-5250-6810
Nico ForrazCTIPharma Department, Cell Therapy Research Institute, CTIBIOTECH, Bat A16, 5 Avenue Lionel Terray, Meyzieu, 69330 Lyon, France.ORCID 0000-0001-6875-494X
Clément MiletCTIPharma Department, Cell Therapy Research Institute, CTIBIOTECH, Bat A16, 5 Avenue Lionel Terray, Meyzieu, 69330 Lyon, France.ORCID 0000-0002-4431-8147
Mathieu LacroixCTIPharma Department, Cell Therapy Research Institute, CTIBIOTECH, Bat A16, 5 Avenue Lionel Terray, Meyzieu, 69330 Lyon, France.ORCID 0009-0005-8996-6497
Yordan SbirkovDepartment of Medical Biology and Research Institute, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria.ORCID 0000-0002-6554-3773
Victoria SarafianDepartment of Medical Biology and Research Institute, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria.ORCID 0000-0003-1501-0175
Caroline EbelTransgene, Illkirch-Graffenstaden, 67400 Strasbourg, France.
Anita SpindlerTransgene, Illkirch-Graffenstaden, 67400 Strasbourg, France.
Véronique KoerperTransgene, Illkirch-Graffenstaden, 67400 Strasbourg, France.
Jean-Marc BalloulTransgene, Illkirch-Graffenstaden, 67400 Strasbourg, France.
Eric QuéméneurTransgene, Illkirch-Graffenstaden, 67400 Strasbourg, France.ORCID 0000-0002-6450-043X
Cécile ZaupaTransgene, Illkirch-Graffenstaden, 67400 Strasbourg, France.
Transgene (France) · FRMedical University Plovdiv · BG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long-term modelization of cancer as it changes in the human body is a difficult goal, particularly when designing and testing new therapeutic strategies. This becomes even more difficult with metastasis modeling to show chemotherapeutic molecule delivery directly to tumoral cells. Advanced therapeutics, including oncolytic viruses, antibody-based and cell-based therapies are increasing. The question is, are screening tests also evolving? Next-generation therapeutics need equally advanced screening tests, which whilst difficult to achieve, are the goal of our work here, creating models of micro- and macrotumors using 3D bioprinting. We developed advanced colorectal cancer tumor processing techniques to provide options for cellular expansion, microtumor printing, and long-term models, which allow for the evaluation of the kinetics of penetration testing, therapeutic success, targeted therapies, and personalized medicine. We describe how we tested tumors from a primary colorectal patient and, applying 3D bioprinting, matured long-term models for oncolytic metastatic screening. Three-dimensional microtumors were kept alive for the longest time ever recorded in vitro, allowing longitudinal studies, screening of oncolytic viruses and realistic modelization of colorectal cancer. These 3D bioprinted models were maintained for around 6 months and were able to demonstrate the effective delivery of a product to the tumoral environment and represent a step forward in therapeutic screening.

Indexed as

3D bioprintingcolorectallongitudinaloncolytic virus

Identifiers

PMID37835418
PMCPMC10571882
OpenAlexW4387056539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.